Regarding second- and third-line therapy, two trials conducted globally and in Asia showed favorable activity and a manageable safety profile for PD-1 inhibitors in patients with refractory advanced gastric cancer or gastroesophageal junction cancer (GEJC) who had received at least two prior therapies (12, 13). Here, PDCD1 is linked to gastric cancer.